8 analysts out of 8 Wall Street brokerage firms rate MEI Pharma, Inc. (NASDAQ:MEIP) as a Buy, while 0 see it as a Sell. The rest 0 describe it as a Hold. MEIP stock traded higher to an intra-day high of $2.55. At one point in session, its potential discontinued and the price was down to lows at $2.42. Analysts have set MEIP’s consensus price at $8.19, effectively giving it a 226.29% projection on returns. Should the projected estimates be met, then the stock will likely hit its highest price at $11 (up 338.25% from current price levels). MEIP has a -86.2% ROE, lower than the 10.05% average for the industry. The average ROE for the sector is 15.24%.
It is expected that in Jun 2019 quarter MEIP will have an EPS of $-0.2, suggesting a -53.85% growth. For Sep 2019 is projected at $-0.29. It means that there could be a -107.14% growth in the quarter. Yearly earnings are expected to rise by 9.46% to about $-0.67. As for the coming year, growth will be about -17.91%, lifting earnings to $-0.79. RSI after the last trading period was 23.71. MEIP recorded a change of -10.04% over the past week and returned -16.33% over the last three months while the MEIP stock’s monthly performance revealed a shift in price of -17.97%. The year to date (YTD) performance stands at -4.92%, and the bi-yearly performance specified an activity trend of -3.09% while the shares have moved -49.29% for the past 12 months.
MEI Pharma, Inc. (MEIP) currently trades at $2.51, which is lower by -0.4% its previous price. It has a total of 71.55 million outstanding shares, with an ATR of around 0.15. The company’s stock volume dropped to 1.19 million, worse than 172.27 thousands that represents its 50-day average. A 5-day decrease of about -10.04% in its price means MEIP is now -4.92% lower on year-to-date. The shares have surrendered $43458.49 since its $4.96 52-week high price recorded on 17th of September 2018. Overall, it has seen a growth rate of -49.29 over the last 12 months. The current price per share is $0.69 above the 52 week low of $1.82 set on 27th of December 2018.
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares depreciated -4.55% over the last trading period, taking overall 5-day performance up to -28.72%. SLS’s price now at $0.42 is weaker than the 50-day average of $0.85. Getting the trading period increased to 200 days, the stock price was seen at $1.27 on average. The general public currently hold control of a total of 24.7 million shares, which is the number publicly available for trading. The total of shares that it has issued to investors is 27.93 million. The company’s management holds a total of 1.7%, while institutional investors hold about 20.1% of the remaining shares. SLS share price finished last trade -36.33% below its 20 day simple moving average and its downbeat gap from 200 day simple moving average is -67%, while closing the session with -51.22% distance from 50 day simple moving average.
SELLAS Life Sciences Group, Inc. (SLS) shares were last observed trading -92.28% down since June 12, 2018 when the peak of $5.44 was hit. Last month’s price growth of -54.84% puts SLS performance for the year now at -65.85%. Consequently, the shares price is trending higher by -2.33%, a 52-week worst price since Jun. 11, 2019. However, it is losing value with -75.44% in the last 6 months. From a technical perspective, it appears more likely that the stock will experience a Bull Run market as a result of the strong support seen recently between $0.36 and $0.39. The immediate resistance area is now $0.46 Williams’s %R (14) for SLS moved to 96.17 while the stochastic %K points at 5.22.
Estimated quarterly earnings for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) are around $-0.18 per share in three months through June with $-0.19 also the estimate for September quarter of the fiscal year. It means the growth is estimated at 85.71% and 64.15%, respectively. Analysts estimate full-year growth to be 74.16%, the target being $-0.85 a share. The upcoming year will see an increase in growth by percentage to -16.47%, more likely to see it hit the $-0.99 per share. The firm’s current profit margin over the past 12 months is 0%. SLS ranks higher in comparison to an average of -7.22% for industry peers; while the average for the sector is -12.3%.